Damien C Weber

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7739461/publications.pdf

Version: 2024-02-01

57758 62596 7,675 162 44 80 citations h-index g-index papers 166 166 166 7345 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. Journal of Neurosurgery, 2015, 122, 4-23.	1.6	500
2	Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro-Oncology, 2017, 19, 162-174.	1.2	381
3	Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for $1p/19q$ non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet, The, 2017, 390, 1645-1653.	13.7	307
4	ESTRO-ACROP guideline "target delineation of glioblastomas― Radiotherapy and Oncology, 2016, 118, 35-42.	0.6	286
5	Treatment planning and verification of proton therapy using spot scanning: Initial experiences. Medical Physics, 2004, 31, 3150-3157.	3.0	243
6	EANO guideline on the diagnosis and management of meningiomas. Neuro-Oncology, 2021, 23, 1821-1834.	1.2	230
7	Atypical and Malignant Meningioma: Outcome and Prognostic Factors in 119 Irradiated Patients. A Multicenter, Retrospective Study of the Rare Cancer Network. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1388-1393.	0.8	197
8	Results of spot-scanning proton radiation therapy for chordoma and chondrosarcoma of the skull base: The Paul Scherrer Institut experience. International Journal of Radiation Oncology Biology Physics, 2005, 63, 401-409.	0.8	195
9	The ROAM/EORTC-1308 trial: Radiation versus Observation following surgical resection of Atypical Meningioma: study protocol for a randomised controlled trial. Trials, 2015, 16, 519.	1.6	165
10	Incidence and relative survival of chordomas. Cancer, 2013, 119, 2029-2037.	4.1	160
11	QA makes a clinical trial stronger: Evidence-based medicine in radiation therapy. Radiotherapy and Oncology, 2012, 105, 4-8.	0.6	152
12	Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol \tilde{A}^3 gica, 2013, 52, 1622-1628.	1.8	144
13	Long term outcomes of patients with skull-base low-grade chondrosarcoma and chordoma patients treated with pencil beam scanning proton therapy. Radiotherapy and Oncology, 2016, 120, 169-174.	0.6	136
14	Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: A phase-II parallel non-randomized and observation study (EORTC 22042-26042). Radiotherapy and Oncology, 2018, 128, 260-265.	0.6	123
15	Towards FLASH proton therapy: the impact of treatment planning and machine characteristics on achievable dose rates. Acta Oncol \tilde{A}^3 gica, 2019, 58, 1463-1469.	1.8	119
16	Proton Beam Radiosurgery for Vestibular Schwannoma: Tumor Control and Cranial Nerve Toxicity. Neurosurgery, 2003, 53, 577-588.	1.1	114
17	A treatment planning comparison of intensity modulated photon and proton therapy for paraspinal sarcomas. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1596-1606.	0.8	113
18	Radiation dose constraints for organs at risk in neuro-oncology; the European Particle Therapy Network consensus. Radiotherapy and Oncology, 2018, 128, 26-36.	0.6	112

#	Article	IF	Citations
19	[(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma. Radiation Oncology, 2008, 3, 44.	2.7	109
20	Spot-scanning proton radiation therapy for recurrent, residual or untreated intracranial meningiomas. Radiotherapy and Oncology, 2004, 71, 251-258.	0.6	94
21	Involved-Node and Involved-Field Volumetric Modulated Arc vs. Fixed Beam Intensity-Modulated Radiotherapy for Female Patients With Early-Stage Supra-Diaphragmatic Hodgkin Lymphoma: A Comparative Planning Study. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1578-1586.	0.8	93
22	"Radiobiology of Proton Therapy†Results of an international expert workshop. Radiotherapy and Oncology, 2018, 128, 56-67.	0.6	85
23	Quality assurance for prospective EORTC radiation oncology trials: The challenges of advanced technology in a multicenter international setting. Radiotherapy and Oncology, 2011, 100, 150-156.	0.6	80
24	The EPTN consensus-based atlas for CT- and MR-based contouring in neuro-oncology. Radiotherapy and Oncology, 2018, 128, 37-43.	0.6	80
25	Long-term outcome of patients with spinal myxopapillary ependymoma: treatment results from the MD Anderson Cancer Center and institutions from the Rare Cancer Network. Neuro-Oncology, 2015, 17, 588-595.	1.2	79
26	The Role of Radio- and Chemotherapy in Glioblastoma. Oncology Research and Treatment, 2005, 28, 315-317.	1.2	77
27	Spot Scanning-Based Proton Therapy for Intracranial Meningioma: Long-Term Results From the Paul Scherrer Institute. International Journal of Radiation Oncology Biology Physics, 2012, 83, 865-871.	0.8	77
28	Prospective Pilot Study of Sildenafil for Treatment of Postradiotherapy Erectile Dysfunction in Patients With Prostate Cancer. Journal of Clinical Oncology, 1999, 17, 3444-3449.	1.6	76
29	Cranio-spinal irradiation with volumetric modulated arc therapy: A multi-institutional treatment experience. Radiotherapy and Oncology, 2011, 99, 79-85.	0.6	73
30	Practice Patterns Analysis of Ocular Proton Therapy Centers: The International OPTIC Survey. International Journal of Radiation Oncology Biology Physics, 2016, 95, 336-343.	0.8	69
31	Visual outcome of accelerated fractionated radiation for advanced sinonasal malignancies employing photons/protons. Radiotherapy and Oncology, 2006, 81, 243-249.	0.6	68
32	Predicted Risk of Radiation-Induced Cancers After Involved Field and Involved Node Radiotherapy With or Without Intensity Modulation for Early-Stage Hodgkin Lymphoma in Female Patients. International Journal of Radiation Oncology Biology Physics, 2011, 81, 490-497.	0.8	66
33	Proton beam radiotherapy versus fractionated stereotactic radiotherapy for uveal melanomas: A comparative study. International Journal of Radiation Oncology Biology Physics, 2005, 63, 373-384.	0.8	65
34	Recurrence pattern after [(18)F]Fluoroethyltyrosine-Positron Emission Tomography-guided radiotherapy for high-grade glioma: A prospective study. Radiotherapy and Oncology, 2009, 93, 586-592.	0.6	64
35	Outcome and prognostic factors in cerebellar glioblastoma multiforme in adults: A retrospective study from the Rare Cancer Network. International Journal of Radiation Oncology Biology Physics, 2006, 66, 179-186.	0.8	59
36	Low rectal toxicity after dose escalated IMRT treatment of prostate cancer using an absorbable hydrogel for increasing and maintaining space between the rectum and prostate: Results of a multi-institutional phase II trial. Radiotherapy and Oncology, 2013, 106, 215-219.	0.6	59

#	Article	lF	Citations
37	Radiation therapy quality assurance in clinical trials $\hat{a} \in Global$ harmonisation group. Radiotherapy and Oncology, 2014, 111, 327-329.	0.6	55
38	An evaluation of rescanning technique for liver tumour treatments using a commercial PBS proton therapy system. Radiotherapy and Oncology, 2016, 121, 281-287.	0.6	54
39	Respiratory motion-management in stereotactic body radiation therapy for lung cancer – A dosimetric comparison in an anthropomorphic lung phantom (LuCa). Radiotherapy and Oncology, 2016, 121, 328-334.	0.6	52
40	Long-term outcomes and prognostic factors of skull-base chondrosarcoma patients treated with pencil-beam scanning proton therapy at the Paul Scherrer Institute. Neuro-Oncology, 2016, 18, 236-243.	1.2	51
41	RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: a treatment planning comparison study. Radiation Oncology, 2009, 4, 34.	2.7	50
42	Particle therapy in Europe. Molecular Oncology, 2020, 14, 1492-1499.	4.6	50
43	Relative survival of patients with supratentorial low-grade gliomas. Neuro-Oncology, 2012, 14, 1062-1069.	1.2	48
44	Intensity Modulated Proton and Photon Therapy for Early Prostate Cancer With or Without Transperineal Injection of a Polyethylen Glycol Spacer: A Treatment Planning Comparison Study. International Journal of Radiation Oncology Biology Physics, 2012, 84, e311-e318.	0.8	47
45	Tumour control and Quality of Life in children with rhabdomyosarcoma treated with pencil beam scanning proton therapy. Radiotherapy and Oncology, 2016, 120, 163-168.	0.6	46
46	Proton therapy for pediatric malignancies: Fact, figures and costs. A joint consensus statement from the pediatric subcommittee of PTCOG, PROS and EPTN. Radiotherapy and Oncology, 2018, 128, 44-55.	0.6	46
47	Radiation therapy planning with photons and protons for early and advanced breast cancer: an overview. Radiation Oncology, 2006, 1 , 22 .	2.7	45
48	Global Harmonization of Quality Assurance Naming Conventions in Radiation Therapy Clinical Trials. International Journal of Radiation Oncology Biology Physics, 2014, 90, 1242-1249.	0.8	44
49	Pencil beam scanning proton therapy for pediatric intracranial ependymoma. Journal of Neuro-Oncology, 2016, 128, 137-145.	2.9	44
50	A statistical comparison of motion mitigation performances and robustness of various pencil beam scanned proton systems for liver tumour treatments. Radiotherapy and Oncology, 2018, 128, 182-188.	0.6	44
51	Assessment of dosimetric errors induced by deformable image registration methods in 4D pencil beam scanned proton treatment planning for liver tumours. Radiotherapy and Oncology, 2018, 128, 174-181.	0.6	43
52	Patterns of proton therapy use in pediatric cancer management in 2016: An international survey. Radiotherapy and Oncology, 2019, 132, 155-161.	0.6	42
53	ESTRO ACROP guideline for target volume delineation of skull base tumors. Radiotherapy and Oncology, 2021, 156, 80-94.	0.6	41
54	A Treatment Planning Comparison of Combined Photon–Proton Beams Versus Proton Beams–Only for the Treatment of Skull Base Tumors. International Journal of Radiation Oncology Biology Physics, 2007, 69, 944-954.	0.8	40

#	Article	IF	CITATIONS
55	Atypical meningoma: current management dilemmas and prospective clinical trials. Journal of Neuro-Oncology, 2015, 121, 1-7.	2.9	39
56	Deformable image registration uncertainty for inter-fractional dose accumulation of lung cancer proton therapy. Radiotherapy and Oncology, 2020, 147, 178-185.	0.6	39
57	Effect of Anatomic Changes on Pencil Beam Scanned Proton Dose Distributions for Cranial and Extracranial Tumors. International Journal of Radiation Oncology Biology Physics, 2017, 97, 616-623.	0.8	38
58	Anatomical robust optimization to account for nasal cavity filling variation during intensity-modulated proton therapy: a comparison with conventional and adaptive planning strategies. Physics in Medicine and Biology, 2018, 63, 025020.	3.0	38
59	New pathology classification, imagery techniques and prospective trials for meningiomas: the future looks bright. Current Opinion in Neurology, 2010, 23, 563-570.	3.6	37
60	Long term outcome of skull-base chondrosarcoma patients treated with high-dose proton therapy with or without conventional radiation therapy. Radiotherapy and Oncology, 2018, 129, 520-526.	0.6	37
61	The prognostic value of expression of HIF1α, EGFR and VEGF-A, in localized prostate cancer for intermediate- and high-risk patients treated with radiation therapy with or without androgen deprivation therapy. Radiation Oncology, 2012, 7, 66.	2.7	36
62	Commissioning of a clinical pencil beam scanning proton therapy unit for ultraâ€high dose rates (FLASH). Medical Physics, 2021, 48, 4017-4026.	3.0	36
63	Tumor control and QoL outcomes of very young children with atypical teratoid/rhabdoid Tumor treated with focal only chemo-radiation therapy using pencil beam scanning proton therapy. Journal of Neuro-Oncology, 2015, 121, 389-397.	2.9	35
64	Long-Term Outcomes and Prognostic Factors After Pencil-Beam Scanning Proton Radiation Therapy for Spinal Chordomas: A Large, Single-Institution Cohort. International Journal of Radiation Oncology Biology Physics, 2018, 101, 226-233.	0.8	35
65	Quality assurance in the EORTC 22033–26033/CE5 phase III randomized trial for low grade glioma: The digital individual case review. Radiotherapy and Oncology, 2012, 103, 287-292.	0.6	34
66	Pencil Beam Scanning Proton Therapy for Pediatric Parameningeal Rhabdomyosarcomas: Clinical Outcome of Patients Treated at the Paul Scherrer Institute. Pediatric Blood and Cancer, 2016, 63, 1731-1736.	1.5	34
67	Profile of European proton and carbon ion therapy centers assessed by the EORTC facility questionnaire. Radiotherapy and Oncology, 2017, 124, 185-189.	0.6	33
68	Long-Term Clinical Outcomes of Pencil Beam Scanning Proton Therapy for Benign and Non-benign Intracranial Meningiomas. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1190-1198.	0.8	33
69	EORTC Radiation Oncology Group quality assurance platform: Establishment of a digital central review facility. Radiotherapy and Oncology, 2012, 103, 279-286.	0.6	32
70	Treatment log files as a tool to identify treatment plan sensitivity to inaccuracies in scanned proton beam delivery. Radiotherapy and Oncology, 2017, 125, 514-519.	0.6	32
71	Daily adaptive proton therapy – the key to innovative planning approaches for paranasal cancer treatments. Acta Oncológica, 2019, 58, 1423-1428.	1.8	32
72	Update of the EPTN atlas for CT- and MR-based contouring in Neuro-Oncology. Radiotherapy and Oncology, 2021, 160, 259-265.	0.6	32

#	Article	IF	CITATIONS
73	Feasibility of Pencil Beam Scanned Intensity Modulated Proton Therapy in Breath-hold for Locally Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1121-1128.	0.8	30
74	Four-Dimensional Dose Reconstruction for Scanned Proton Therapy Using Liver 4DCT-MRI. International Journal of Radiation Oncology Biology Physics, 2016, 95, 216-223.	0.8	29
75	Clival chordoma: a single-centre outcome analysis. Acta Neurochirurgica, 2017, 159, 1815-1823.	1.7	29
76	Intensity modulated proton therapy plan generation in under ten seconds. Acta Oncol \tilde{A}^3 gica, 2019, 58, 1435-1439.	1.8	29
77	Highâ€doseâ€rate brachytherapy boost to the dominant intraâ€prostatic tumor region: Hemiâ€rradiation of prostate cancer. Prostate, 2011, 71, 1309-1316.	2.3	28
78	Radiotherapy versus Observation following surgical resection of Atypical Meningioma (the ROAM) Tj ETQq0 0 0 rg	gBT/Overl	၀င္ငန္ 10 Tf 50
79	Dose-painting intensity-modulated proton therapy for intermediate- and high-risk meningioma. Radiation Oncology, 2015, 10, 72.	2.7	28
80	Quality assurance of radiotherapy in the ongoing EORTC 22042–26042 trial for atypical and malignant meningioma: results from the dummy runs and prospective individual case Reviews. Radiation Oncology, 2013, 8, 23.	2.7	26
81	IMRT credentialing for prospective trials using institutional virtual phantoms: results of a joint European Organization for the Research and Treatment of Cancer and Radiological Physics Center project. Radiation Oncology, 2014, 9, 123.	2.7	26
82	Simultaneous in-field boost for patients with 1 to 4 brain metastasis/es treated with volumetric modulated arc therapy: a prospective study on quality-of-life. Radiation Oncology, 2011, 6 , 79 .	2.7	25
83	Radiation Necrosis and White Matter Lesions inÂPediatric Patients With Brain Tumors Treated With Pencil Beam Scanning Proton Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 100, 987-996.	0.8	25
84	Adjuvant or radical fractionated stereotactic radiotherapy for patients with pituitary functional and nonfunctional macroadenoma. Radiation Oncology, 2011, 6, 169.	2.7	24
85	Dose-adapted salvage radiotherapy after radical prostatectomy based on an erMRI target definition model: Toxicity analysis. Acta Oncológica, 2014, 53, 96-102.	1.8	24
86	Outcome impact and cost-effectiveness of quality assurance for radiotherapy planned for the EORTC 22071–24071 prospective study for head and neck cancer. Radiotherapy and Oncology, 2014, 111, 393-399.	0.6	24
87	Current practice in proton therapy delivery in adult cancer patients across Europe. Radiotherapy and Oncology, 2022, 167, 7-13.	0.6	23
88	Liquid fiducial marker applicability in proton therapy of locally advanced lung cancer. Radiotherapy and Oncology, 2017, 122, 393-399.	0.6	22
89	Assessment of target dose delivery in anal cancer using in vivo thermoluminescent dosimetry. Radiotherapy and Oncology, 2001, 59, 39-43.	0.6	21
90	Dummy run and conformity indices in the ongoing EORTC low-grade glioma trial 22033-26033: First evaluation of quality of radiotherapy planning. Radiotherapy and Oncology, 2010, 95, 218-224.	0.6	21

#	Article	IF	CITATIONS
91	Could hyperthermia with proton therapy mimic carbon ion therapy? Exploring a thermo-radiobiological rationale. International Journal of Hyperthermia, 2014, 30, 524-530.	2.5	21
92	Proton therapy for brain tumours in the area of evidence-based medicine. British Journal of Radiology, 2020, 93, 20190237.	2.2	21
93	Pencil beam scanning proton therapy for the treatment of craniopharyngioma complicated with radiation-induced cerebral vasculopathies: A dosimetric and linear energy transfer (LET) evaluation. Radiotherapy and Oncology, 2020, 149, 197-204.	0.6	21
94	Prospective data registration and clinical trials for particle therapy in Europe. Radiotherapy and Oncology, 2018, 128, 9-13.	0.6	20
95	Radiation-induced optic neuropathy after pencil beam scanning proton therapy for skull-base and head and neck tumours. British Journal of Radiology, 2020, 93, 20190028.	2.2	20
96	Long-Term Clinical Safety of High-Dose Proton Radiation Therapy Delivered With Pencil Beam Scanning Technique for Extracranial Chordomas and Chondrosarcomas in Adult Patients: Clinical Evidence of Spinal Cord Tolerance. International Journal of Radiation Oncology Biology Physics, 2018, 100, 218-225.	0.8	19
97	Optimizing clinical research and generating prospective high-quality data in particle therapy in Europe: Introducing the European Particle Therapy Network (EPTN). Radiotherapy and Oncology, 2018, 128, 1-3.	0.6	19
98	Bladder opacification does not significantly influence dose distribution in conformal radiotherapy of prostate cancer. Radiotherapy and Oncology, 2001, 59, 95-97.	0.6	18
99	Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma. Strahlentherapie Und Onkologie, 2014, 190, 864-871.	2.0	16
100	Quality assurance of radiotherapy in the ongoing EORTC 1219-DAHANCA-29 trial for HPV/p16 negative squamous cell carcinoma of the head and neck: Results of the benchmark case procedure. Radiotherapy and Oncology, 2017, 123, 424-430.	0.6	16
101	Impact of beam angle choice on pencil beam scanning breath-hold proton therapy for lung lesions. Acta Oncol \tilde{A}^3 gica, 2017, 56, 853-859.	1.8	16
102	Daily Adaptive Proton Therapy: Is it Appropriate to Use Analytical Dose Calculations for Plan Adaption?. International Journal of Radiation Oncology Biology Physics, 2020, 107, 747-755.	0.8	16
103	Dosimetric influence of deformable image registration uncertainties on propagated structures for online daily adaptive proton therapy of lung cancer patients. Radiotherapy and Oncology, 2021, 159, 136-143.	0.6	16
104	Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma― Individual case review analysis. Radiotherapy and Oncology, 2018, 127, 292-298.	0.6	15
105	Evaluation of the ray-casting analytical algorithm for pencil beam scanning proton therapy. Physics in Medicine and Biology, 2019, 64, 065021.	3.0	15
106	Clinical outcomes and quality of life in children and adolescents with primary brain tumors treated with pencil beam scanning proton therapy. Pediatric Blood and Cancer, 2020, 67, e28465.	1.5	15
107	Proton therapy and the European Particle Therapy Network: The past, present and future. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2020, 24, 687-690.	1.4	15
108	Pencil beam scanned protons for the treatment of patients with Ewing sarcoma. Pediatric Blood and Cancer, 2017, 64, e26688.	1.5	14

#	Article	IF	CITATIONS
109	Bringing Europe together in building clinical evidence for proton therapy – the EPTN–ESTRO–EORTC endeavor. Acta Oncológica, 2019, 58, 1340-1342.	1.8	14
110	Whole-ventricular irradiation for intracranial germ cell tumors: Dosimetric comparison of pencil beam scanned protons, intensity-modulated radiotherapy and volumetric-modulated arc therapy. Clinical and Translational Radiation Oncology, 2019, 15, 53-61.	1.7	14
111	Commissioning and quality assurance of a novel solution for respiratory-gated PBS proton therapy based on optical tracking of surface markers. Zeitschrift Fur Medizinische Physik, 2022, 32, 52-62.	1.5	14
112	Clinical outcomes of head and neck adenoid cystic carcinoma patients treated with pencil beam-scanning proton therapy. Oral Oncology, 2020, 107, 104752.	1.5	14
113	Proton Irradiation with Hyperthermia in Unresectable Soft Tissue Sarcoma. International Journal of Particle Therapy, 2016, 3, 327-336.	1.8	14
114	Proton Therapy for Intracranial Meningioma for the Treatment of Primary/Recurrent Disease Including Re-Irradiation. Frontiers in Oncology, 2020, 10, 558845.	2.8	14
115	Range resolution and reproducibility of a dedicated phantom for proton PBS daily quality assurance. Zeitschrift Fur Medizinische Physik, 2018, 28, 310-317.	1.5	13
116	Radiotherapy quality assurance of SBRT for patients with centrally located lung tumours within the multicentre phase II EORTC Lungtech trial: Benchmark case results. Radiotherapy and Oncology, 2019, 132, 63-69.	0.6	13
117	Quality assurance for the EORTC 22071–26071 study: dummy run prospective analysis. Radiation Oncology, 2014, 9, 248.	2.7	12
118	Noninvasive eye localization in ocular proton therapy through optical eye tracking: A proof of concept. Medical Physics, 2018, 45, 2186-2194.	3.0	12
119	Dosimetric analysis of local failures in skull-base chordoma and chondrosarcoma following pencil beam scanning proton therapy. Radiation Oncology, 2020, 15, 266.	2.7	12
120	Impact of internal target volume definition for pencil beam scanned proton treatment planning in the presence of respiratory motion variability for lung cancer: A proof of concept. Radiotherapy and Oncology, 2020, 145, 154-161.	0.6	12
121	Prognostic factors for spinal chordomas and chondrosarcomas treated with postoperative pencil-beam scanning proton therapy: a large, single-institution experience. Journal of Neurosurgery: Spine, 2020, 32, 921-930.	1.7	12
122	Quality assurance of four-dimensional computed tomography in a multicentre trial of stereotactic body radiotherapy of centrally located lung tumours. Physics and Imaging in Radiation Oncology, 2018, 8, 57-62.	2.9	11
123	Early results and volumetric analysis after spot-scanning proton therapy with concomitant hyperthermia in large inoperable sacral chordomas. British Journal of Radiology, 2020, 93, 20180883.	2.2	11
124	Practice Considerations for Proton Beam Radiation Therapy of Uveal Melanoma During the Coronavirus Disease Pandemic: Particle Therapy Co-Operative Group Ocular Experience. Advances in Radiation Oncology, 2020, 5, 682-686.	1.2	11
125	Potential and pitfalls of 1.5T MRI imaging for target volume definition in ocular proton therapy. Radiotherapy and Oncology, 2021, 154, 53-59.	0.6	11
126	Combining rescanning and gating for a time-efficient treatment of mobile tumors using pencil beam scanning proton therapy. Radiotherapy and Oncology, 2021, 160, 82-89.	0.6	11

#	Article	IF	CITATIONS
127	Dose–response curves for MRI-detected radiation-induced temporal lobe reactions in patients after proton and carbon ion therapy: Does the same RBE-weighted dose lead to the same biological effect?. Radiotherapy and Oncology, 2018, 128, 109-114.	0.6	10
128	Stereotactic Radiotherapy for Ocular Melanoma: Initial Experience Using Closed Eyes for Ocular Target Immobilization. Technology in Cancer Research and Treatment, 2007, 6, 413-417.	1.9	9
129	Quality assurance standards drive improvements in the profile of radiation therapy departments participating in trials of the EORTC Radiation Oncology Group. Radiotherapy and Oncology, 2014, 112, 376-380.	0.6	9
130	Combining Clinical and Dosimetric Features in a PBS Proton Therapy Cohort to Develop a NTCP Model for Radiation-Induced Optic Neuropathy. International Journal of Radiation Oncology Biology Physics, 2021, 110, 587-595.	0.8	9
131	Radiologic Patterns of Necrosis After Proton Therapy of Skull Base Tumors. Canadian Journal of Neurological Sciences, 2013, 40, 800-806.	0.5	8
132	Results of a multicentre dosimetry audit using a respiratory phantom within the EORTC LungTech trial. Radiotherapy and Oncology, 2019, 138, 106-113.	0.6	8
133	Outcomes of adolescents and young adults treated for brain and skull base tumors with pencil beam scanning proton therapy. Pediatric Blood and Cancer, 2020, 67, e28664.	1.5	8
134	Good long-term visual outcomes of parapapillary choroidal melanoma patients treated with proton therapy: a comparative study. International Ophthalmology, 2021, 41, 441-452.	1.4	8
135	Intensity modulated radiation therapy or stereotactic fractionated radiotherapy for infratentorial ependymoma in children: a multicentric study. Journal of Neuro-Oncology, 2011, 102, 295-300.	2.9	7
136	A predictive algorithm for spot position corrections after fast energy switching in proton pencil beam scanning. Medical Physics, 2018, 45, 4806-4815.	3.0	7
137	The dosimetric effect of residual breath-hold motion in pencil beam scanned proton therapy – An experimental study. Radiotherapy and Oncology, 2019, 134, 135-142.	0.6	7
138	Pitfalls in the beam modelling process of Monte Carlo calculations for proton pencil beam scanning. British Journal of Radiology, 2020, 93, 20190919.	2.2	7
139	Clinical and Radiologic Outcomes in Adults and Children Treated with Pencil-Beam Scanning Proton Therapy for Low-Grade Glioma. International Journal of Particle Therapy, 2017, 3, 450-460.	1.8	7
140	Prognostic impact of the "Sekhar grading system for cranial Chordomas―in patients treated with pencil beam scanning proton therapy: an institutional analysis. Radiation Oncology, 2020, 15, 96.	2.7	6
141	Dose Escalation Study with Two Different Hypofractionated Intensity Modulated Radiotherapy Techniques for Localized Prostate Cancer: Acute Toxicity. Technology in Cancer Research and Treatment, 2010, 9, 263-270.	1.9	4
142	Combination of Proton Therapy and Radionuclide Therapy in Mice: Preclinical Pilot Study at the Paul Scherrer Institute. Pharmaceutics, 2019, 11, 450.	4.5	4
143	Technical Note: Benchmarking automated eye tracking and human detection for motion monitoring in ocular proton therapy. Medical Physics, 2020, 47, 2237-2241.	3.0	4
144	Benchmarking a commercial proton therapy solution: The Paul Scherrer Institut experience. British Journal of Radiology, 2020, 93, 20190920.	2.2	4

#	Article	IF	CITATIONS
145	EORTC Radiation Oncology Group: 50 years of continuous accomplishments. European Journal of Cancer, Supplement, 2012, 10, 150-159.	2.2	3
146	OP18LONG TERM OUTCOMES OF SKULL-BASE LOW-GRADE CHONDROSARCOMA PATIENTS TREATED WITH PENCIL BEAM SCANNING PROTON THERAPY AT THE PAUL SCHERRER INSTITUTE. Neuro-Oncology, 2015, 17, viii3.4-viii3.	1.2	3
147	The dependence of interplay effects on the field scan direction in PBS proton therapy. Physics in Medicine and Biology, 2019, 64, 095005.	3.0	3
148	A Prospective Study on Health-Related Quality of Life and Patient-Reported Outcomes in Adult Brain Tumor Patients Treated with Pencil Beam Scanning Proton Therapy. Cancers, 2021, 13, 4892.	3.7	3
149	Letter to the Editor. Phase III randomized controlled trials are essential to properly evaluate the role of radiotherapy in WHO grade II meningioma. Journal of Neurosurgery, 2018, 129, 1104-1105.	1.6	2
150	Influence of Radiation Dose, Photon Energy, and Reconstruction Kernel on rho/z Analysis in Spectral Computer Tomography: A Phantom Study. In Vivo, 2022, 36, 678-686.	1.3	2
151	Treatment planning comparison in the PROTECT-trial randomising proton versus photon beam therapy in oesophageal cancer: Results from eight European centres. Radiotherapy and Oncology, 2022, 172, 32-41.	0.6	2
152	The Rate of Secondary Malignancies After Radical Prostatectomy Versus External Beam Radiation Therapy for Localized Prostate Cancer: A Population-Based Study On 17,845 Patients. In Regard to Bhojani etÂal. (Int J Radiat Oncol Biol Phys 2010;76:342–348.). International Journal of Radiation Oncology Biology Physics, 2010, 78, 314-315.	0.8	1
153	Letter to the Editor: SEER analysis and statistical judgment. Journal of Neurosurgery, 2014, 120, 578-579.	1.6	1
154	Ectopic Recurrence of Skull Base Chordoma after Proton Therapy. Current Oncology, 2022, 29, 2364-2375.	2.2	1
155	Reply to the Letter to the editor on Cranio-spinal irradiation with volumetric modulated arc therapy by G. Saini et al Radiotherapy and Oncology, 2012, 102, 322-323.	0.6	0
156	GERM-09. WHOLE VENTRICULAR IRRADIATION FOR INTRACRANIAL GERM CELL TUMORS: DOSIMETRIC COMPARISON OF PENCIL BEAM SCANNED PROTONS VS. IMRT. Neuro-Oncology, 2018, 20, i85-i85.	1.2	0
157	Reply to Laprie A. et al. Radiotherapy and Oncology, 2019, 130, 194.	0.6	0
158	A multi-institutional clinical trial of rectal dose reduction via injected polyethylene-glycol hydrogel during IMRT for prostate cancer: Analysis of dosimetric outcomes Journal of Clinical Oncology, 2013, 31, 35-35.	1.6	0
159	Particle Therapy Clinical Trials., 2018, , 181-192.		O
160	Re: Koga et al. A case of primary mucosa-associated lymphoid tissue lymphoma of the prostate. Rare Tumors, 2009, 1, e56.	0.6	0
161	Re: Koga et al. A case of primary mucosa-associated lymphoid tissue lymphoma of the prostate. Rare Tumors, 2009, 1, 171-171.	0.6	0
162	RONC-02. Clinical outcome after craniospinal irradiation with pencil beam scanning proton therapy for children and young adults/adolescents with brain tumors. Neuro-Oncology, 2022, 24, i176-i176.	1.2	0